These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 37750467)

  • 1. Characterization and discrimination of spike protein in SARS-CoV-2 virus-like particles via surface-enhanced Raman spectroscopy.
    Akdeniz M; Al-Shaebi Z; Altunbek M; Bayraktar C; Kayabolen A; Bagci-Onder T; Aydin O
    Biotechnol J; 2024 Jan; 19(1):e2300191. PubMed ID: 37750467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pseudotyping Improves the Yield of Functional SARS-CoV-2 Virus-like Particles (VLPs) as Tools for Vaccine and Therapeutic Development.
    Zak AJ; Hoang T; Yee CM; Rizvi SM; Prabhu P; Wen F
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Production, purification and immunogenicity of Gag virus-like particles carrying SARS-CoV-2 components.
    Gashti AB; Agbayani G; Hrapovic S; Nassoury N; Coulombe N; Dudani R; Harrison BA; Akache B; Gilbert R; Chahal PS
    Vaccine; 2024 Jan; 42(1):40-52. PubMed ID: 38042697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical evaluation of manufacturable SARS-CoV-2 spike virus-like particles produced in Chinese Hamster Ovary cells.
    Alpuche-Lazcano SP; Stuible M; Akache B; Tran A; Kelly J; Hrapovic S; Robotham A; Haqqani A; Star A; Renner TM; Blouin J; Maltais JS; Cass B; Cui K; Cho JY; Wang X; Zoubchenok D; Dudani R; Duque D; McCluskie MJ; Durocher Y
    Commun Med (Lond); 2023 Aug; 3(1):116. PubMed ID: 37612423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of Fluorescence-Tagged SARS-CoV-2 Virus-like Particles by a Tri-Cistronic Vector Expression System for Investigating the Cellular Entry of SARS-CoV-2.
    Chang YS; Chu LW; Chen ZY; Wu JS; Su WC; Yang CJ; Ping YH; Lin CW
    Viruses; 2022 Dec; 14(12):. PubMed ID: 36560829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mammalian cells-based platforms for the generation of SARS-CoV-2 virus-like particles.
    Elfayres G; Paswan RR; Sika L; Girard MP; Khalfi S; Letanneur C; Milette K; Singh A; Kobinger G; Berthoux L
    J Virol Methods; 2023 Dec; 322():114835. PubMed ID: 37871706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid and quantitative detection of respiratory viruses using surface-enhanced Raman spectroscopy and machine learning.
    Yang Y; Xu B; Murray J; Haverstick J; Chen X; Tripp RA; Zhao Y
    Biosens Bioelectron; 2022 Dec; 217():114721. PubMed ID: 36152394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Label-Free Detection of the Receptor-Binding Domain of the SARS-CoV-2 Spike Glycoprotein at Physiologically Relevant Concentrations Using Surface-Enhanced Raman Spectroscopy.
    Sarychev AK; Sukhanova A; Ivanov AV; Bykov IV; Bakholdin NV; Vasina DV; Gushchin VA; Tkachuk AP; Nifontova G; Samokhvalov PS; Karaulov A; Nabiev I
    Biosensors (Basel); 2022 May; 12(5):. PubMed ID: 35624601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 Virus-like Particles with Plasmonic Au Cores and S1-Spike Protein Coronas.
    Andrzejewska W; Peplińska B; Litowczenko J; Obstarczyk P; Olesiak-Bańska J; Jurga S; Lewandowski M
    ACS Synth Biol; 2023 Aug; 12(8):2320-2328. PubMed ID: 37449651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
    Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virus-Like Particles of SARS-CoV-2 as Virus Surrogates: Morphology, Immunogenicity, and Internalization in Neuronal Cells.
    Kumar CS; Singh B; Rizvi ZA; Parray HA; Verma JK; Ghosh S; Mukhopadhyay A; Awasthi A; Shrivastava T; Banerjee M
    ACS Infect Dis; 2022 Oct; 8(10):2119-2132. PubMed ID: 36129193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasmonic nanostructure-enhanced Raman scattering for detection of SARS-CoV-2 nucleocapsid protein and spike protein variants.
    Yeh YJ; Le TN; Hsiao WW; Tung KL; Ostrikov KK; Chiang WH
    Anal Chim Acta; 2023 Jan; 1239():340651. PubMed ID: 36628748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional assessments of SARS-CoV-2 single-round infectious particles with variant-specific spike proteins on infectivity, drug sensitivity, and antibody neutralization.
    Su WC; Chen ZY; Chang YS; Jeng KS; Le UNP; Chou YC; Kuo LL; Melano I; Jesse ; Wang WJ; Song YC; Li SR; Hung MC; Lai MMC; Lin CW
    Antiviral Res; 2023 Dec; 220():105744. PubMed ID: 37944823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ultra-fast and onsite interrogation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in waters via surface enhanced Raman scattering (SERS).
    Zhang D; Zhang X; Ma R; Deng S; Wang X; Wang X; Zhang X; Huang X; Liu Y; Li G; Qu J; Zhu Y; Li J
    Water Res; 2021 Jul; 200():117243. PubMed ID: 34029872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Machine learning-driven SERS fingerprinting of disintegrated viral components for rapid detection of SARS-CoV-2 in environmental dust.
    Garg A; Hawks S; Pan J; Wang W; Duggal N; Marr LC; Vikesland P; Zhou W
    Biosens Bioelectron; 2024 Mar; 247():115946. PubMed ID: 38141443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Efficient and Scalable Method for the Production of Immunogenic SARS-CoV-2 Virus-like Particles (VLP) from a Mammalian Suspension Cell Line.
    Hirschberg S; Ghazaani F; Ben Amor G; Pydde M; Nagel A; Germani S; Monica L; Schlör A; Bauer H; Hornung J; Voetz M; Dwai Y; Scheer B; Ringel F; Kamal-Eddin O; Harms C; Füner J; Adrian L; Pruß A; Schulze-Forster K; Hanack K; Kamhieh-Milz J
    Vaccines (Basel); 2023 Sep; 11(9):. PubMed ID: 37766145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimal system for assembly of SARS-CoV-2 virus like particles.
    Swann H; Sharma A; Preece B; Peterson A; Eldredge C; Belnap DM; Vershinin M; Saffarian S
    Sci Rep; 2020 Dec; 10(1):21877. PubMed ID: 33318562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimized production and fluorescent labeling of SARS-CoV-2 virus-like particles.
    Gourdelier M; Swain J; Arone C; Mouttou A; Bracquemond D; Merida P; Saffarian S; Lyonnais S; Favard C; Muriaux D
    Sci Rep; 2022 Aug; 12(1):14651. PubMed ID: 36030323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inclusion of cGAMP within virus-like particle vaccines enhances their immunogenicity.
    Chauveau L; Bridgeman A; Tan TK; Beveridge R; Frost JN; Rijal P; Pedroza-Pacheco I; Partridge T; Gilbert-Jaramillo J; Knight ML; Liu X; Russell RA; Borrow P; Drakesmith H; Townsend AR; Rehwinkel J
    EMBO Rep; 2021 Aug; 22(8):e52447. PubMed ID: 34142428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV.
    Liu YV; Massare MJ; Barnard DL; Kort T; Nathan M; Wang L; Smith G
    Vaccine; 2011 Sep; 29(38):6606-13. PubMed ID: 21762752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.